Chinese State-Owned Funds Invest in Biotech Firm MabPlex

Login to View

MabPlex International, a Chinese biologics development and manufacturing solutions provider, has completed a RMB400 million (US$59.1 million) series A round of financing. The round was led by China’s state-owned SDIC Venture Capital and Shenzhen Capital Group, an investment unit of Shenzhen Municipal Government, according to an announcement today.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in

China Money Network Subscription